BrightGene

同壁财经 · May 30 at 10:12 AM

BrightGene has continuously received a Wind ESG A rating, with a comprehensive score of 7.53

prnewswire · May 12 at 01:10 AM

02:08 ETGIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena

prnewswire · May 6 at 11:12 AM

12:10 ET19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities

prnewswire · May 5 at 07:22 AM

08:20 ETBGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

CoinLive · May 5 at 04:13 AM

BGM0504 Injection Achieves Phase III Clinical Trial Goals for Weight Loss

Wallstreetcn · Apr 14 at 10:30 PM

April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively